CAMBRIDGE, Mass., Sept. 22, 2010 (GLOBE NEWSWIRE) — Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that Phase 1 data of its novel Hedgehog pathway inhibitor, IPI-926, will be presented during the 35th Congress of the European Society of Molecular Oncology (ESMO), in Milan, Italy.
The poster, entitled “A Phase 1 study of IPI-926, an inhibitor of the [...] http://bit.ly/aXhVYI
No comments:
Post a Comment